Skip to main content
ADVB
NASDAQ Industrial Applications And Services

Advanced Biomed Q1 Loss Widens to $989K; Cash Down to $214K After $613K Credit Charge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.38
Mkt Cap
$5.469M
52W Low
$1.8
52W High
$24.229
52W Position info
88% above low
Off High info
86% below high
Rel. Volume info
8.0× avg
Market data snapshot near publication time

ADVB sits 88% above its 52-week low of $1.8 on elevated volume (8.0× avg).

Summary

Advanced Biomed posted a $989,054 quarterly loss with no revenue and only $213,995 of cash, while adding a $612,636 credit-loss provision against $15.0M owed by its divested subsidiaries.


Key Events · Earnings and Guidance · ADVB

  • Quarterly Loss Widens Sharply

    Net loss was $989,054 for the three months ended September 30, 2026, versus $386,901 a year earlier, on zero revenue from continuing operations.

  • Credit Provision Hits Earnings

    G&A of $973,931 included a $612,636 expected credit-loss provision, mostly a $630,360 addition on amounts due from former subsidiaries.

  • Cash Position Very Thin

    Cash fell to $213,995 from $385,535 at June 30, 2026; the $11,276,618 working capital is dominated by $12,329,466 of net receivables from divested subsidiaries.

  • Equity Line Terminated

    The company terminated its equity line of credit effective July 21, 2026, with no outstanding advances at the time.


Analysis · ADVB · Industrial Applications And Services

There is still essentially no operating business here: zero revenue in the quarter, and the loss more than doubled to $989,054 from $386,901 a year earlier. Most of the damage comes from a $612,636 non-cash credit-loss provision on $15.0M owed by the subsidiaries it sold off — money the company is owed but may not collect. With cash on hand of only $213,995, the $11.3M of reported working capital is almost entirely those receivables, not spendable cash. Management says it has twelve months of liquidity, but that depends on collecting from the former subsidiaries or raising more money. And the equity line of credit was terminated in July, removing one financing backstop.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADVB was trading at $3.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.80 to $24.23. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADVB - Latest Insights

ADVB
Oct 13, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.18
Real-time Price: $2.40 info
Change: -$2.78 (-54%) info
Market Cap: $4.18M info
ADVB
Jul 17, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.46
Real-time Price: $2.40 info
Change: -$3.06 (-56%) info
Market Cap: $4.18M info
ADVB
Jul 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.03
Real-time Price: $2.40 info
Change: -$2.63 (-52%) info
Market Cap: $4.18M info
ADVB
Jun 30, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $2.40 info
Change: -$2.30 (-49%) info
Market Cap: $4.18M info
ADVB
Jun 04, 2026, 7:30 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $4.60
Real-time Price: $2.40 info
Change: -$2.20 (-48%) info
Market Cap: $4.18M info